Questions for your doctor? Download guide now

Understanding Treatment

Starting HERZUMA

Questions and answers about starting HERZUMA

WHAT you should tell your doctor before starting HERZUMA

Before receiving HERZUMA, tell your doctor if you:

Have trouble with your heart. HERZUMA can cause heart problems in some patients
Are pregnant or plan to become pregnant. Trastuzumab products can cause fetal harm when administered to a pregnant woman. Because trastuzumab stays in the body for a long time, you should avoid becoming pregnant for 7 months after discontinuing HERZUMA
Are taking any other medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements

Know the medicines you take. Keep a list of them to show to your doctor and pharmacist when you get a new medicine. Do not take any new medicine without speaking with your doctor.

NEXT QUESTION Expand All

WHY IS HEART MONITORING NECESSARY WHILE RECEIVING HERZUMA THERAPY?

Your healthcare team will monitor your heart for potential cardiac issues to detect them early on so they can be properly treated.

Your heart will be monitored at the start of treatment, every 3 months while on HERZUMA therapy, and every 6 months for at least 2 years following completion of HERZUMA as a component of adjuvant therapy. Heart function will be tested with an ECHO* or MUGA scan.^†

*ECHO scan is an ultrasound image of the heart.

^†MUGA scan takes a moving picture of your heart pumping blood following an injection of a nontoxic radioactive substance.

During HERZUMA therapy

Pausing HERZUMA
- In case of reduced heart function, your doctor may hold HERZUMA therapy up to 3 times
Restarting HERZUMA
- Your doctor may restart HERZUMA therapy up to 3 times if your heart function improves and returns to normal limits after HERZUMA has been held
Discontinuing HERZUMA
- HERZUMA will be discontinued if you experience congestive heart failure (CHF) or significantly reduced heart function (when the heart can’t keep up with the amount of blood flowing through it)

After HERZUMA therapy

Your heart should be monitored every 6 months for at least 2 years

NEXT QUESTION

HOW WILL YOU RECEIVE HERZUMA?

HERZUMA is given by infusion through a needle placed in a vein (intravenous infusion) in your arm, or through a port
Talk to your doctor to find out whether you will receive HERZUMA in an infusion center or in your doctor's office
The first dose of HERZUMA takes about 90 minutes. After that, the other doses of HERZUMA only take about 30 minutes

NEXT QUESTION

WILL YOU HAVE TO TAKE ANY MEDICINE BEFORE YOU RECEIVE HERZUMA?

Your healthcare provider may prescribe medicines before each infusion of HERZUMA to reduce infusion side effects such as fever and chills
Taking the suggested medication before treatment may reduce the chance of having a severe reaction during the first HERZUMA infusion
Be sure to ask your doctor or nurse about what you should take before HERZUMA treatment

NEXT QUESTION

HOW WILL YOUR DOCTOR CHECK UP ON YOU DURING TREATMENT?

Your doctor should do blood tests and monitor your heart regularly to check for side effects to HERZUMA
Before each HERZUMA treatment, your healthcare provider will ask you questions about your general health. Tell your healthcare provider about any new symptoms

NEXT QUESTION

HOW CAN YOU GET READY FOR YOUR HERZUMA INFUSION?

5 things to help prepare yourself before every infusion:

Plan Transportation To and From Your Infusion Appointment
You may feel exhausted after your infusion, so having someone else drive you home after treatments is a good idea.
Bring Something To Pass the Time
A day at the clinic can be long. Reading magazines, completing a word search, or enjoying a similar activity can help you occupy the time.
Bring Food and Beverages
You may be at the clinic for most of the day, so pack some snacks or a light meal and bring a water bottle.
Tell Your Doctor or Nurse About Medicines You Are Taking
If you take any other medicines, tell your doctor or nurse. Do not start any new medications without talking to your doctor. Your doctor may give you special instructions for your infusion day.
Speak Up
Tell your doctor or nurse about any concerns you have.

Looking to save on the cost of HERZUMA?

Learn about potential savings

APPROVED USES

Patients are selected for therapy with HERZUMA based on an FDA-approved test.

Adjuvant Breast Cancer

HERZUMA is a prescription medicine used in adults for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature. HERZUMA can be used in several different ways:

As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC → TH”
With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as “TCH”
Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin)-based therapy (a type of chemotherapy)

Metastatic Breast Cancer

HERZUMA has 2 approved uses in metastatic breast cancer in adults:

HERZUMA in combination with the chemotherapy drug paclitaxel is approved for the first-line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer
HERZUMA alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease

Metastatic Gastric Cancer

HERZUMA is approved in adults, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease

IMPORTANT SAFETY INFORMATION

HERZUMA can cause serious side effects, including:

HEART PROBLEMS: Trastuzumab products can cause heart problems—such as congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both a trastuzumab product and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your healthcare provider will check for signs of heart problems before, during, and after treatment with HERZUMA
INFUSION REACTIONS: Infusion reactions, sometimes serious or fatal, have occurred. Symptoms may include: fever, chills, feeling sick to your stomach (nausea), throwing up (vomiting), pain (in some cases at tumor site), headache, dizziness, and shortness of breath. These symptoms usually happen within 24 hours after receiving HERZUMA
SEVERE LUNG PROBLEMS: Trastuzumab product use can result in serious and fatal lung problems. Symptoms may include: severe shortness of breath, fluid in or around the lungs, weakening of the valve between the heart and lungs, not enough oxygen in the body, swelling of the lungs, and scarring of the lungs. Your healthcare provider may check for signs of severe lung problems
HARM TO UNBORN BABIES OR BIRTH DEFECTS: Trastuzumab products may result in birth defects or the death of an unborn baby. Contraception should be used while receiving HERZUMA and for 7 months after your last dose of HERZUMA. If you are or become pregnant while receiving HERZUMA or within 7 months after your last dose of HERZUMA, you should immediately contact your doctor. Patients should contact their healthcare professional with a known or suspected pregnancy
LOW WHITE BLOOD CELL COUNTS: Low white blood cell counts (which may be life-threatening) were seen more often in patients receiving trastuzumab plus chemotherapy than in patients receiving chemotherapy alone. Your healthcare provider may check for signs of low white blood cell counts

Your healthcare provider will stop treatment with HERZUMA if you have severe, serious, or life-threatening side effects.

The most common side effects for patients receiving HERZUMA for breast cancer include: headache, diarrhea, feeling sick to your stomach (nausea), chills, fever, infection, weakened heart muscle, unable to sleep, cough, and rash.

The most common side effects for patients receiving HERZUMA for metastatic gastric cancer include: low white blood cell counts, diarrhea, feeling tired, low red blood cell counts, swelling of the mouth lining, weight loss, upper respiratory infections, fever, low platelet counts, swelling of the mucous membranes, swelling of the nose and throat, and change in taste.

These are not all of the possible side effects with HERZUMA.

Please click here for full Prescribing Information for HERZUMA, including BOXED WARNINGS.

Talk to your doctor about any side effects you may experience.

You may report side effects to Teva at 1-888-483-8279. You may also report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.